CHMP recommends Velsipity (etrasimod) for the treatment of ulcerative colitis – Pfizer

On 14 December 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Velsipity, intended for the treatment of ulcerative colitis. The applicant for this medicinal product is Pfizer Europe. Velsipity will be available as a 2 mg film-coated tablet. The active substance of Velsipity […]

Frequent use of antibiotics may heighten inflammatory bowel disease risk in over 40s

Frequent use of antibiotics may heighten the risk of inflammatory bowel disease—Crohn’s disease and ulcerative colitis—among the over 40s, suggests research published online in the journal Gut. The risk seems to be cumulative and greatest 1-2 years after use and for those antibiotics targeting gut infections, the findings indicate. Mounting evidence suggests that environmental factors are likely implicated in the development […]

Inflammatory bowel disease increases risks for pregnant women

Pregnant women with inflammatory bowel disease (IBD) and their babies face increased risks and complications compared to pregnant women without IBD. Those are the findings from a new University of Missouri School of Medicine study that examined outcomes of more than 8 million pregnancies. IBD is a term used for Crohn’s disease and ulcerative colitis, which are characterized by chronic […]